Breaking Down SG&A Expenses: Arrowhead Pharmaceuticals, Inc. vs Galapagos NV

A Comparative Analysis of SG&A Expenses: Arrowhead Pharmaceuticals vs. Galapagos NV

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Arrowhead Pharmaceuticals, Inc. and Galapagos NV from 2014 to 2023. Over this period, Arrowhead Pharmaceuticals saw a significant increase in SG&A expenses, peaking in 2022 with a 410% rise from 2014. Meanwhile, Galapagos NV experienced a more volatile trajectory, with expenses surging by over 250% in 2022 compared to 2014, before a notable decline in 2023.

The data reveals that both companies have strategically invested in their administrative and sales functions, albeit with different patterns. Arrowhead's consistent growth contrasts with Galapagos' fluctuating expenses, highlighting diverse strategic approaches. Notably, the absence of data for Galapagos in 2024 suggests a potential shift or restructuring in their financial reporting.